Yahoo · Oct 1, 2026
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.
RP
NASDAQ · RPRX
Royalty Pharma plc
Healthcare · Biotechnology
$57.16
Down-$0.50 (-0.87%)
Updated Oct 6, 2026, 12:02 AM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 16.85B
- P/E ratio
- 16.44
- Dividend yield
- 1.54%
- 52-week range
- $35.23 – $64.38
- Volume
- 2.23M
- Avg. volume
- 4.22M
Price performance · RPRX
RPRX price history
1M range · 0 trading sessions · Daily adjusted prices
RPRX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest RPRX news
The latest Smart Investors Daily articles mentioning RPRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RPRX research
Overview
Company profile and research snapshot.
Company profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $47.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 13, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | Citigroup | Buy | — |
| May 7, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 29, 2026
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of
Yahoo · Sep 25, 2026
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage. Speaking during a firesid
SeekingAlpha · Sep 23, 2026
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Bank of America Global Healthcare Conference 2026 September 23, 2026 6:45 AM EDTCompany ParticipantsTerrance Coyne - Executive VP...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
